Search results
Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie
Motley Fool· 1 year agoVertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) both beat last year's bear market....
AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell?
Motley Fool· 7 months agoAbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are makers of two of the world's top-selling...
Could This Drug News Lift AbbVie's Stock?
Motley Fool· 1 year agoConsider AbbVie's (NYSE: ABBV) crown jewel drug, Humira, which hauled in $21.2 billion in revenue in 2022. The good news is that AbbVie knew this day...
AbbVie's Blockbuster Is Falling Fast. Time to Sell?
Motley Fool· 1 year agoLast week wasn't a great one for a lot of pharmaceutical stock investors. Shares of AbbVie (NYSE: ABBV) dropped by about 8% on Thursday, April 27. The...
Do Humira Biosimilars Threaten AbbVie's Dividend?
Motley Fool· 1 year agoPharmaceutical giant AbbVie (NYSE: ABBV) is known for its top-selling drug Humira and its lucrative dividend that yields more than 4% at the current...
Better Growth Stock: Abbott vs. AbbVie
Motley Fool via Yahoo Finance· 5 months agoAbbott Laboratories (NYSE: ABT) and AbbVie (NYSE: ABBV) share a common past. About a decade ago, Abbott spun out its pharmaceuticals business into a...
2 Reasons to Buy AbbVie, and 1 Reason to Sell
Motley Fool· 1 year agoAbbVie (NYSE: ABBV) wowed investors last year when it outperformed the S&P 500 index. Shares of the pharmaceutical company climbed 19%, while the...
AbbVie to buy immune drug developer Landos
BioPharma Dive via Yahoo Finance· 2 months agoDive Brief: Abbvie is expanding its pipeline of inflammatory disease drugs, announcing Monday a small deal to acquire biotechnology company Landos...
AbbVie's $21 Billion Drug Humira Is on the Decline. Should You Still Buy This Dividend Stock?
Motley Fool· 7 months agoFor the past couple of years, investors looked ahead to one particular thing with dread: AbbVie's...
Vertex Pharmaceuticals Just Lost a Potential Rival. Is the Stock a Buy?
Motley Fool· 1 year agoVertex Pharmaceuticals (NASDAQ: VRTX) is the global leader in cystic fibrosis (CF) treatment. The...
